Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With Cash position of $7.4 million and now new market in Brazilian.. anouth reserve to get approval from FDA. Must survive!
"Received feedback from the U.S. Food and Drug Administration (FDA) on the 510(k) submission for Tearlab Discovery™ Platform; plans to submit response in Q3"
https://finance.yahoo.com/news/tearlab-corporation-reports-first-quarter-200100857.html?.tsrc=rss&guccounter=1
"First Quarter and Recent Highlights
First quarter revenue of $6.4 million
Income from operations of $0.2 million, compared to operating loss of $3.4 million in first quarter 2017
Expanded the U.S. active device base to 4,713 TearLab Osmolarity Systems
Received feedback from the U.S. Food and Drug Administration (FDA) on the 510(k) submission for Tearlab Discovery™ Platform; plans to submit response in Q3
Launched the TearLab Osmolarity System at the 2018 Simpósio Internacional Moacyr Álvaro (SIMASP) Annual Meeting in Brazil in collaboration with Brazilian commercial partner, Adapt Produtos Oftalmológicos
Amended loan agreement with CRG to defer the cash interest payments for each quarter in fiscal year 2018 and reduce the minimum liquidity requirement from $5.0 million to $3.0 million.
Entered into Restated License Agreement with UCSD to reduce royalty from 5.5% to 3%, retroactive to July 1, 2017
Cash position of $7.4 million as of March 31, 2018"
&&&&&&&&&&&
"2018 is an important year for TearLab, as we work to achieve FDA clearance for the TearLab Discovery™ System in the U.S. and execute against our new business model,” said Seph Jensen, TearLab’s Chief Executive Officer. “In the first quarter of 2018, we grew our customer base while significantly reducing operating expenses, which demonstrates the health of our core business. In addition, we launched our Osmolarity System in Brazil, Latin America’s largest dry eye market, at the 2018 SIMASP Annual Meeting with the support of our commercial partner in Brazil, Adapt. Overall it was a very positive quarter and we believe our results demonstrate the growing awareness and importance of advanced diagnostics for ocular surface disease.”
Large volume selling.....did they not get FDA approval? Financials do look good but no FDA approval will send this stock to trip land
One main question to me. Can this comp. survive now ??
Quite a burn rate.
If it can survive or get taken out, this is a great buying op.....
JMHO
Hawk
.166 now. Im buying. The financials look great and confused why there is not more volume. With more good news we climb.
Could someone please explain the numbers to me, was it a good quarter / development? Much less loss ... over 7.million cash and therefore triple in cash than the market capitalization .. anyway we are at 0.24 usd
THANKS
Do anyone know, when will the Fourth Quarter and Full Year 2017 Results
come out? Thanks!
Got in at .45 today but only $had 60
Really just to humor a friend who has some stock alert app . Had $1500 on saleen and thats in the toilet .
Even though this was a wolf pump and dump looking at the chart it is definitely do for a run, and if you got in under .45 your losses won't be to bad
Pump and dump = bad
Then save your money my friend. You obviously have a lot to learn or a lot of money to lose first.
Im new at penny stocks . Is that good or bad ?
The Wolf <thewolf@thewolfofpennystocks.com>
not sure what you mean
It was a Wolf alerted ticker
This will pop back up don’t be fooled
not holding anymore. good products, very bad Management. let this stock moved to OTC.
Ash you still excited on TEAR or cutting losses.
We will know more when the Q3 is filed on the 13th. I did a little buying at .59 yesterday.
TEAR delisted from the Nasdaq to the OTC:
http://otce.finra.org/DLAdditions
Delisting is going to keep this down for awhile unless the Q is good which I doubt. If ash111 liked it at 1.45 he will love it here lol.
HUGE haircut AH
Not good news =(
Doubtful. The volume was extremely low.
I think the numbers are leaking out and thus the drop. Will we stay above 52 week low of $1.20 maybe not.
TEAR.
TearLab Corporation to Release Third Quarter 2017 Financial Results on November 13, 2017
Print
Alert
Tearlab Corp. (MM) (NASDAQ:TEAR)
Intraday Stock Chart
Today : Wednesday 1 November 2017
Click Here for more Tearlab Corp. (MM) Charts.
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) will announce its third quarter 2017 financial results after market close on Monday, November 13, 2017.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Third Quarter 2017 Results Conference Call Details:
Date: Monday, November 13, 2017
Time: 4:30 p.m. ET
Live Call: 877-303-1593 (Pass Code: 1089456)
Replay: 855-859-2056 (Pass Code: 1089456)
The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section.
Nice early trading and moving thru 50 day MA will need to close above 1.50 to get buyers. Ask way out of balance to bid right now 9000 vs 100
This is getting ready fly. The cavalry is coming.
Nice support and if we get continued price increase with higher volume then it's time to load. Today's volume not strong enough to get really excited imo.
Possible retest of the 1.20-1.25 range here. If it goes lower then I don't see much upside. If it bounces off this area probably time to load wheelbarrow.
Looks like it might be on its way to printing new lows...looking for good entry :)
TEAR interesting coverage forecast sales of $145m on only a modest market penetration. Edison 14 May 2015 : "If it can achieve even modest market penetration it may reach potential yearly card sales of $145m. This assumes 10% provider penetration, 25 patients per day, 25% of patients tested and 175 clinic days per year".
Edison also said that "The current EV of $73.4m", "May not reflect market potential". Cutrent EV is only $10m, extremely undervalued relating EV mentioned.
TEAR Security Details
Share Structure
Market Value1 $9,934,444
a/o Oct 06, 2017
This coverage was written exactly 2 years ago before TEAR Achieved those Milestones (Achieved more than a modest market penetration as Edison forecasted):
1. Approval in the Republic of Korea by the Ministry of Health and Welfare
2. Commercial launch in the Republic of India
3. A/o May 12, 2017- approval in the Federative Republic of Brazil (the largest market in Latin America with a population of over 200 million).
CEO of TearLab Corporation said, "We are pleased to complete these major milestones for TearLab’s international business as we continue to increase our global footprint in key strategic markets. Due to their size and growing dry eye populations, these three markets represent significant opportunity for us to expand our business and continue toward our goal of making osmolarity testing a global standard of care in diagnosing dry eye disease.”
4. CE Mark.
Strong IP Portfolio:
U.S. 11 Issued Patents
ROW 25 Issued Patents
Pending 18 Patents
TearLab Corporation currently has a consensus rating of “Buy” and a consensus price target of $4.90.
https://www.thestockobserver.com/2017/10/06/tearlab-corporation-tear-sees-unusually-high-trading-volume.html/amp
DD: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=135132249
Oct 7-11,2017 Lisbon, European Society of Cataract and Refractive Surgeons (ESCRS), Tearlab will display its new Discovery Systems.
TearLab Corporation currently has a consensus rating of “Buy” and a consensus price target of $4.90.
https://www.thestockobserver.com/2017/10/06/tearlab-corporation-tear-sees-unusually-high-trading-volume.html/amp
DD: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=135132249
Oct 7-11,2017 Lisbon, European Society of Cataract and Refractive Surgeons (ESCRS), Tearlab will display its new Discovery Systems.
On a tear. http://www.escrs.org/lisbon2017/virtual-exhibition.asp?l=t&location=
Next week will get exposure.
You welcome. So many catalysts, could throw a bomb anytime. Also presents next week. Doing $28m and all points of revenues boost thru Q4 and behind. Broke MA50 which is also a bullish technical sign.
TEAR thanks Ash111, went long today.
My thoughts exactly
ST profits for many.
News and day traders were in.
Another op. for next trip.....
GLA
Hawk
is this just a morning sell off?
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
438
|
Created
|
12/07/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |